查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402921

类风湿性关节炎药物市场（药物类型：非类固醇抗发炎药、皮质类固醇、疾病修饰抗风湿药和生物反应调节剂）-全球产业分析、规模、份额、成长、趋势和预测，2023-2031

Rheumatoid Arthritis Drugs Market (Drug Type: Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Disease Modifying Anti-rheumatic Drugs, & Biologic Response Modifiers) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 173 Pages | 商品交期: 2-10个工作天内

价格

类风湿性关节炎药物市场 - 报告范围

TMR 关于全球类风湿关节炎药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球类风湿关节炎药物的收入2017-2031年期间的市场，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球类风湿关节炎药物市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解类风湿关节炎药物市场。

市场概况
2023年市场价值 175 亿美元
2031 年市场价值 293 亿美元
CAGR 5.7%

该报告深入探讨了全球类风湿性关节炎药物市场的竞争格局。全球类风湿性关节炎药物市场的主要参与者已经确定，并且每位参与者都根据不同的属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球类风湿关节炎药物市场参与者的属性。

目录

第 1 章：执行摘要

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 市场区隔
  • 概述
  • 市场动态
  • 2022-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要国家的进展
  • COVID-19 大流行对该行业的影响

第 6 章：市场分析与预测：依药物类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2023-2031
    • 非类固醇类抗发炎药 (NSAID)
    • 皮质类固醇
    • 疾病缓解抗风湿药物 (DMARD)
    • 生物反应调节剂（生物製剂）
  • 市场吸引力：按药物类型

第 7 章：全球市场分析与预测：按配销通路

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2023-2031
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场吸引力：按配销通路

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2023-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第 14 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • AbbVie Inc.
    • Johnson & Johnson Innovative Medicine
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Sanofi SA
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
Product Code: TMRGL2011

Rheumatoid Arthritis Drugs Market - Scope of Report

TMR's report on the global rheumatoid arthritis drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global rheumatoid arthritis drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatoid arthritis drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the rheumatoid arthritis drugs market.

Market Snapshot
Market Value in 2023US$ 17.5 Bn
Market Value in 2031US$ 29.3 Bn
CAGR5.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatoid arthritis drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatoid arthritis drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatoid arthritis drugs market.

The report delves into the competitive landscape of the global rheumatoid arthritis drugs market. Key players operating in the global rheumatoid arthritis drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatoid arthritis drugs market profiled in this report.

Key Questions Answered in Global rheumatoid arthritis drugs Market Report:

  • What is the sales/revenue generated by rheumatoid arthritis drugs across all regions during the forecast period?
  • What are the opportunities in the global rheumatoid arthritis drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Rheumatoid Arthritis Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global rheumatoid arthritis drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatoid arthritis drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatoid arthritis drugs market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rheumatoid Arthritis Drugs Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, 2022-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Progression in Key Countries
  • 5.3. COVID-19 Pandemic Impact on Industry

6. Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2023-2031
    • 6.3.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 6.3.2. Corticosteroids
    • 6.3.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 6.3.4. Biologic Response Modifiers (Biologics)
  • 6.4. Market Attractiveness, by Drug Type

7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Rheumatoid Arthritis Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Type, 2022-2031
    • 9.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 9.2.2. Corticosteroids
    • 9.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 9.2.4. Biologic Response Modifiers (Biologics)
  • 9.3. Market Value Forecast, by Distribution Channel, 2022-2031
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Value Forecast, by Country, 2022-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Rheumatoid Arthritis Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2022-2031
    • 10.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 10.2.2. Corticosteroids
    • 10.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 10.2.4. Biologic Response Modifiers (Biologics)
  • 10.3. Market Value Forecast, by Distribution Channel, 2022-2031
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Value Forecast, by Country/Sub-region, 2022-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2022-2031
    • 11.2.1. Polycarbonate (PC) Compound
    • 11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 11.2.3. Corticosteroids
    • 11.2.4. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 11.2.5. Biologic Response Modifiers (Biologics)
  • 11.3. Market Value Forecast, by Distribution Channel, 2022-2031
    • 11.3.1. Hospital Pharmacy
    • 11.3.2. Retail Pharmacy
    • 11.3.3. Online Pharmacy
  • 11.4. Market Value Forecast, by Country/Sub-region, 2022-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Rheumatoid Arthritis Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2022-2031
    • 12.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 12.2.2. Corticosteroids
    • 12.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 12.2.4. Biologic Response Modifiers (Biologics)
  • 12.3. Market Value Forecast, by Distribution Channel, 2022-2031
    • 12.3.1. Hospital Pharmacy
    • 12.3.2. Retail Pharmacy
    • 12.3.3. Online Pharmacy
  • 12.4. Market Value Forecast, by Country/Sub-region, 2022-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2022-2031
    • 13.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 13.2.2. Corticosteroids
    • 13.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
    • 13.2.4. Biologic Response Modifiers (Biologics)
  • 13.3. Market Value Forecast, by Distribution Channel, 2022-2031
    • 13.3.1. Hospital Pharmacy
    • 13.3.2. Retail Pharmacy
    • 13.3.3. Online Pharmacy
  • 13.4. Market Value Forecast, by Country/Sub-region, 2022-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. AbbVie Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Johnson & Johnson Innovative Medicine
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Amgen Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Pfizer Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novartis AG
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Sanofi S.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. F. Hoffmann-La Roche Ltd.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Merck & Co., Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Bristol-Myers Squibb Company
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Eli Lilly and Company
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview

List of Tables

  • Table 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 2: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 3: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Region, 2023-2031
  • Table 4: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country, 2023-2031
  • Table 5: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 6: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 7: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 8: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 9: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 10: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 11: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 12: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 13: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 15: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 16: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 17: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023-2031
  • Table 18: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031

List of Figures

  • Figure 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 2: Global Rheumatoid Arthritis Drugs Market Value Share, by Drug Type, 2022
  • Figure 3: Global Rheumatoid Arthritis Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 4: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 5: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 6: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 7: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 8: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 9: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 11: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 14: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 15: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 16: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 17: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 18: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 21: Europe America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 22: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 23: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 24: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 25: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 28: Asia Pacific America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 29: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 32: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 35: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 36: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2023-2031
  • Figure 39: Middle East & Africa America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 40: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 41: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 42: Global Rheumatoid Arthritis Drugs Market Share Analysis, by Company (2022)